Highlights

  • Micro-X (ASX:MX1) is turning long-running cold-cathode, carbon-nanotube X-ray research into multiple commercial and pre-commercial programs across health, defence and security.
  • Its Rover Plus mobile X-ray system was approved for nationwide US procurement, giving more than 700 hospitals direct purchasing access.
  • The company has activated its first human trial site for a world-first portable Head CT stroke scanner at Royal Melbourne Hospital, backed by a A$4.4m government grant for a stroke-capable ambulance program.
  • Micro-X passed a critical design review under its US ARPA-H full-body mobile CT contract and secured a US$6.0m US Homeland Security extension for airport self-screening checkpoints.
  • Despite the milestones, Micro-X is still loss-making and has repeatedly raised capital, most recently a small discounted placement in mid-2026, so dilution and funding risk remain central.

Micro-X Limited (ASX:MX1) has spent the better part of two decades chasing a deceptively simple idea: that the century-old, hot-filament X-ray tube could be replaced by something smaller, lighter and smarter. The Adelaide-based company builds its imaging products around cold-cathode, carbon-nanotube (CNT) emitter technology, which switches X-rays on and off electronically rather than by heating a filament. The promise has always been dramatically reduced size, weight and power — specifications that let an X-ray or CT system be carried in an ambulance, wheeled to a bedside, mounted in an aircraft or built into an airport checkpoint.

For years that promise sat largely in the laboratory. In 2025 and 2026, the narrative has shifted toward genuine commercial and pre-commercial milestones across medical imaging, stroke CT and airport security. The bet is finally beginning to deliver — even as Micro-X remains a small, loss-making company whose progress is inseparable from its need to keep raising money.

What Has Happened

Over roughly the past year, Micro-X has stacked up milestones that touch each of its core markets. In July 2025 it announced that its Rover Plus mobile digital radiography system had been approved for nationwide US procurement, an agreement it said gives more than 700 hospitals direct access to purchase the product. In September 2025 it secured a A$4.4 million grant under the Australian Government's Industry Growth Program to support a world-first stroke-capable ambulance trial integrating its Head CT scanner into emergency services.

The medical CT story advanced further in 2026. In early February the company activated its first human pilot site for the portable Head CT stroke scanner at Royal Melbourne Hospital, home to the Melbourne Brain Centre and supported by the Australian Stroke Alliance. In June it completed the critical design review for its full-body CT — Milestone 7 under a development agreement with the US Advanced Research Projects Agency for Health (ARPA-H) — triggering a A$1.6 million (US$1.2 million) payment and clearing the way to build a first laboratory prototype. On the security side, it secured a US$6.0 million contract extension from the US Department of Homeland Security (DHS) to advance self-screening airport checkpoints ahead of passenger trials.

Why It Matters

The significance is that Micro-X is no longer a single-product story riding on one regulatory outcome. It has assembled a spread of programs, each with a different customer, funding source and timeline, all drawing on the same CNT emitter platform. That diversification reduces reliance on any one approval and shows the technology can attract paying partners across healthcare, defence and security.

It also matters because the technology targets structural problems, not incremental improvements. Stroke care is acutely time-sensitive, yet CT scanners are large, fixed and power-hungry; a portable brain CT that travels to the patient attacks that constraint directly. Rural and remote healthcare lacks imaging infrastructure, precisely the gap the lightweight full-body CT is designed to fill. In each case the value flows from the same physics: making X-ray hardware small and low-power enough to go where conventional equipment cannot.

The Cold-Cathode Platform and Its Product Lines

Micro-X was founded in 2011 and operates a vertically integrated manufacturing facility at Tonsley in South Australia, with a growing team in Seattle. Its defining asset is a proprietary cold-cathode, carbon-nanotube X-ray emitter that dispenses with the heated filament of a conventional tube. Because it can be switched electronically and packaged into compact multi-tube arrays, it enables product designs that are difficult or impossible with legacy tubes.

Mobile imaging: Rover

The Rover family is the company's most commercially mature line — a lightweight, mobile digital radiography (DR) unit for hospital wards, emergency departments and field use. The nationwide US procurement approval for Rover Plus removes a major barrier to sales, giving a large base of US hospitals a straightforward path to buy the system.

Stroke imaging: Head CT

The Head CT program is arguably the most eye-catching. Described as a world-first clinical CT using a curved detector, it is designed to bring brain imaging to the patient — in hospital, an ambulance or even an aircraft. The first human imaging trial site is being commissioned at Royal Melbourne Hospital, with further sites in preparation, generating data intended to support future regulatory applications. A parallel in-ambulance prototype, funded through the Industry Growth Program, underpins the ambition of pre-hospital stroke diagnosis, and the scanner has been selected for a world-first air stroke ambulance study serving remote regions.

Full-body CT: ARPA-H

Under an agreement first announced in November 2024, Micro-X is building a lightweight, ruggedised full-body CT for rural healthcare within the ARPA-H PARADIGM program, a contract valued at up to roughly US$16.4 million (about A$25 million). Passing the critical design review in June 2026 — covering the detector array, multi-tube potted array, high-speed tube switching and system control — moved the project into prototype manufacture.

Security and defence: checkpoints, baggage and Argus

Micro-X's security portfolio includes the DHS-funded self-screening airport checkpoint, a CT-based baggage scanner, and Argus, a backscatter imaging product using miniaturised generators. Rather than fund security commercialisation from its own balance sheet, the company has adopted a partnership model, granting strategic investor Billion Prima security-screening rights for Southeast Asia while it focuses internal resources on medical imaging.

Key Financial and Operational Details

Micro-X remains a developmental business, and its finances reflect that. It is not yet profitable, funding its programs through a mix of government grants, milestone payments and equity raisings. In February 2025 it raised A$6.0 million via a placement and entitlement offer, including A$2.4 million from Billion Prima; in mid-2026 it undertook a smaller placement of 18.75 million shares at A$0.08 each, raising about A$1.5 million, and has also converted convertible notes into equity.

The company's market capitalisation has fluctuated with sentiment and dilution, ranging broadly from the high-A$20 million to the low-A$60 million area across recent reporting, and the shares trade in low single-digit cents. Non-dilutive inflows — the ARPA-H milestone payments, the DHS extension and the A$4.4 million stroke grant — advance the technology without consuming shareholder capital, but the recurring raisings show they have not funded the whole program.

Potential Catalysts

Several near-term events could move the story. Positive human imaging data from the Head CT trial would strengthen the case for eventual regulatory clearance, while delivery and testing of the first ARPA-H full-body CT prototype would validate the portfolio's most ambitious engineering task. Conversion of the DHS checkpoint work into passenger trials would be a visible step toward a security product, and growth in Rover Plus orders plus further partnerships along the Billion Prima model would demonstrate revenue traction.

Material Risks and Uncertainties

The risks are substantial and typical of a pre-commercial medical and security technology company. Micro-X is loss-making and has repeatedly returned to the market for capital, so further dilution is a realistic prospect, with recent raisings priced at a discount. Its flagship medical programs depend on clinical trial outcomes and regulatory approvals that are inherently uncertain and can be slow. Government-funded programs such as ARPA-H and DHS work carry milestone, budget and political risk, and are not guaranteed to convert into ongoing commercial revenue. The company also competes against far larger, better-capitalised incumbents, and none of the current milestones guarantees sustained profitability.

What Investors Should Watch Next

For Micro-X (ASX:MX1), the signposts from here are reasonably clear: imaging data and regulatory progress from the Head CT human trial and the ambulance and air-stroke programs; delivery of the ARPA-H full-body CT prototype and follow-on milestone payments; whether the DHS checkpoint program reaches passenger testing at airports; and Rover Plus sales momentum in the US. Most critically, keep a close eye on the company's cash position, quarterly cash burn and any fresh capital raisings, since funding is the constraint most likely to shape the outcome.

Conclusion

Micro-X (ASX:MX1) has reached an inflection point that few micro-cap technology companies manage: after roughly two decades of research into cold-cathode, carbon-nanotube X-ray technology, it now has real programs with real customers across mobile imaging, stroke CT, full-body CT and airport security. Together, the nationwide US procurement of Rover Plus, human trials of the Head CT scanner, the ARPA-H design-review milestone and the DHS checkpoint extension suggest the underlying platform is credible and increasingly in demand.

Yet the same milestones sit against an unmistakable reality: Micro-X remains loss-making, dependent on continued funding, and exposed to the long, uncertain timelines of clinical, regulatory and government procurement. The bet is beginning to deliver, but delivery is not durable profitability. The key question is whether Micro-X can convert its widening pipeline of milestones into sustainable revenue before its need for capital dilutes the reward.